Hi Sam, this is a very complicated topic. Ive been working in technology transfer for over a decade and in biopharma for years before that. In general I agree with a lot of what you're saying, especially regarding patent waivers. Although big pharma does hide behind the complexity of manufacturing sometimes also. Anyway, like many, you've completely skipped the role of universities/institutes in IP. I wrote this a couple of years ago. May be of interest.
Interesting article but I think you're a bit gung ho with the vaccine roll out. They have to be constantly monitored for safety so going too quick, even in a pandemic, could end up creating more problems than it solves.
Hi Sam, this is a very complicated topic. Ive been working in technology transfer for over a decade and in biopharma for years before that. In general I agree with a lot of what you're saying, especially regarding patent waivers. Although big pharma does hide behind the complexity of manufacturing sometimes also. Anyway, like many, you've completely skipped the role of universities/institutes in IP. I wrote this a couple of years ago. May be of interest.
https://www.irishtimes.com/business/health-pharma/university-know-how-the-secret-sauce-for-vaccine-success-1.4477006
Interesting article but I think you're a bit gung ho with the vaccine roll out. They have to be constantly monitored for safety so going too quick, even in a pandemic, could end up creating more problems than it solves.